Diruthenium(ii,iii) paddlewheel complexes: effects of bridging and axial ligands on anticancer properties

被引:18
|
作者
Tolbatov, Iogann [1 ]
Barresi, Elisabetta [2 ]
Taliani, Sabrina [2 ]
La Mendola, Diego [2 ]
Marzo, Tiziano [2 ]
Marrone, Alessandro [3 ]
机构
[1] Barcelona Inst Sci & Technol, Inst Chem Res Catalonia ICIQ, Ave Paisos Catalans 16, Tarragona 43007, Spain
[2] Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy
[3] Univ G dAnnunzio, Dept Pharm, Via Vestini 31, I-66100 Chieti, Italy
关键词
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IN-VITRO; TETRAACETATE COMPLEXES; IBUPROFEN; COMPOUND; NAPROXEN; PH; PROLIFERATION; RU2CL(IBP)(4); METALLODRUGS;
D O I
10.1039/d3qi00157a
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
This article provides an overview of the application of diruthenium(ii,iii) paddlewheel complexes for anticancer purposes. The use of this coordinative construct is indeed attractive because it provides an excellent opportunity to combine the pharmacological properties of the dimetallic ruthenium center with those derived from the specific choice of ligands bearing a carboxylic function capable of coordination towards the Ru-Ru core. Indeed, the combination of carboxylate ligands with specific anticancer properties and the dimetallic center permits the production of new entities endowed with improved biological profiles. Additionally, these systems allow the simultaneous multiple deliveries of a drug to the target site. Nevertheless, in order to obtain the desired effects, it is mandatory to consider some relevant chemico-physical aspects such as the steric hindrance of the ligands or the possibility of their release under specific biological conditions that should be taken into account in the design of effective complexes. Accordingly, through various examples from the literature, the key features of this family of unconventional compounds are summarized here, also providing useful hints for the design of improved diruthenium(ii,iii) paddlewheel complexes.
引用
收藏
页码:2226 / 2238
页数:13
相关论文
共 50 条
  • [21] Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands
    Starha, Pavel S.
    Krikavova, Radka
    COORDINATION CHEMISTRY REVIEWS, 2024, 501
  • [22] May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents?
    Matos, Cristina P.
    Adiguzel, Zelal
    Yildizhan, Yasemin
    Cevatemre, Buse
    Onder, Tugba Bagci
    Cevik, Ozge
    Nunes, Patrique
    Ferreira, Liliana P.
    Carvalho, Maria Deus
    Campos, Debora L.
    Pavan, Fernando R.
    Pesso, Joao Costa
    Garcia, Maria Helena
    Tomaz, Ana Isabel
    Correia, Isabel
    Acilan, Ceyda
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 176 : 492 - 512
  • [23] Fluorinated Cycloplatinated(II) Complexes Bearing Bisphosphine Ligands as Potent Anticancer Agents
    Shahsavari, Hamid R.
    Hu, Jiyun
    Chamyani, Samira
    Sakamaki, Yoshie
    Aghakhanpour, Reza Babadi
    Salmon, Christopher
    Fereidoonnezhad, Masood
    Mojaddami, Ayyub
    Peyvasteh, Parnian
    Beyzavi, Hudson
    ORGANOMETALLICS, 2021, 40 (01) : 72 - 82
  • [24] Inorganic Frameworks Made by Combining Paddle-wheel Diruthenium(II, III) Complexes and Polyoxometalate Clusters
    Sawada, Yuki
    Yamamoto, Yuma
    Nishio, Masaki
    Kosaka, Wataru
    Hayashi, Yoshihito
    Miyasaka, Hitoshi
    CHEMISTRY LETTERS, 2012, 41 (03) : 212 - 214
  • [25] Substitution-Modulated Anticancer Activity of Half-Sandwich Ruthenium(II) Complexes with Heterocyclic Ancillary Ligands
    Mitra, Raja
    Samuelson, Ashoka G.
    EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2014, (22) : 3536 - 3546
  • [26] Synthesis, characterization and anticancer properties of (salicylaldiminato) platinum(II) complexes
    Patterson, Alyssa E.
    Miller, Jessica J.
    Miles, Brittany A.
    Stewart, Erin L.
    Melanson, Josee-Marie E. J.
    Vogels, Christopher M.
    Cockshutt, Amanda M.
    Decken, Andreas
    Morin, Pier, Jr.
    Westcott, Stephen A.
    INORGANICA CHIMICA ACTA, 2014, 415 : 88 - 94
  • [27] Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer, mechanism
    Qi, Jinxu
    Liang, Shichu
    Gou, Yi
    Zhang, Zhenlei
    Zhou, Zuping
    Yang, Feng
    Liang, Hong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 96 : 360 - 368
  • [28] Rational design of dicarboxylato platinum(II) complexes with purinemimetic ligands as novel anticancer agents
    Hoffmann, Kamil
    Wisniewska, Joanna
    Wojtczak, Andrzej
    Sitkowski, Jerzy
    Denslow, Agnieszka
    Wietrzyk, Joanna
    Jakubowski, Mateusz
    Lakomska, Iwona
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2017, 172 : 34 - 45
  • [29] α-Diimines as Versatile, Derivatizable Ligands in Ruthenium(II) p-Cymene Anticancer Complexes
    Biancalana, Lorenzo
    Batchelor, Lucinda K.
    Funaioli, Tiziana
    Zacchini, Stefano
    Bortoluzzi, Marco
    Pampaloni, Guido
    Dyson, Paul J.
    Marchetti, Fabio
    INORGANIC CHEMISTRY, 2018, 57 (11) : 6669 - 6685
  • [30] Organometallic Iridium(III) Cyclopentadienyl Anticancer Complexes Containing C,N-Chelating Ligands
    Liu, Zhe
    Habtemariam, Abraha
    Pizarro, Ana M.
    Clarkson, Guy J.
    Sadler, Peter J.
    ORGANOMETALLICS, 2011, 30 (17) : 4702 - 4710